The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

UPCOMING EDUCATIONAL OPPORTUNITIES

2024 Annual Meeting

Registration is now open! 

November 1-2, 2024


Lunchtime webinar Series


7/25/24 - Addressing Sexual Health in Patients with Cancer 

Tiffany Hurvitz, BSN, RN, OCN - Merck


RESEARCH, PROJECT & PROGRAM FUNDING


Fall Submission Deadline - September 15th


Fall Submission Deadline

October 15th


Up to $4,000 to fund your educational program.

Rolling Application Deadline

NNECOS PATIENT PHILANTHROPY


Rolling Application Deadline

Up to $3,000 per grant


Rolling Application Deadline

Up to 125, $25 grocery/cards 


OTHER NEWS & INFORMATION

NNECOS Classifieds

  • Northern Light Eastern Maine Medical Center Cancer Care - Clinical Research Nurse Manager

  • Dartmouth Cancer Center - NP or Physician Assistant - Per Diem

  • Dartmouth Cancer Center - NP or Physician Assistant

  • Dartmouth Cancer Center - Hematology Advanced Practice Provider

  • UVM Cancer Center - Faculty Scientist

  • UVM Cancer Center - 

    Medical oncologist/hematologist faculty member on the Clinical 

    Scholar Pathway at the Assistant/Associate level
  • UVM Cancer Center - 

    Physician-scientist/academic clinician to serve as Associate Director of Clinical &

    Translational Research.

  • Beth Israel Lahey Health Exeter -

    Experienced Hematology/Oncology Physician.
  • UVM Medical Center - Clinical Program Coordinator - Hematology 

Drug Shortages Sign On Letter

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!



SOCIAL MEDIA

 

Thank You Corporate Members!


Group Practice Members

Because your entire team benefits
from being a part of NNECOS!

Participate on a NNECOS Task Force


FDA Approvals & uPDATES

Latest FDA Approval

  • June 26, 2024- FDA grants accelerated approval to epcoritamab-bysp for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
  • June 21 - FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
  • June 17 - FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma
  • June 14 - FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
  • June 14 - FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer
  • June 12 - FDA approves selpercatinib for RET fusion-positive thyroid cancer
  • June 6 - FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia
  • May 29 - FDA grants accelerated approval to selpercatinib for pediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumors
  • May 16 - FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
  • May 15 - FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.
  • April 29 - FDA granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.  [now a part of Pfizer Inc.]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. 
  • April 23 - FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
  • April 23 - FDA granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
  • April 22 - FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
  • April 18 - FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer | FDA
  • April 5 - FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors

Package/Label Updates


    Code Updates

    • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
    J1323- Injection, elranatamab-bcmm, 1 mg

    Other Updates


    THANK YOU DIAMOND & PLATINUM CORPORATE MEMBERS


           
       


     

     


         
             
             



    View the complete list of corporate members.




    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software